[
    [
        {
            "time": "",
            "original_text": "【中银医药】博雅生物事件点评：收购无锡罗益生物，跨入疫苗业务新赛道",
            "features": {
                "keywords": [
                    "博雅生物",
                    "收购",
                    "无锡罗益生物",
                    "疫苗",
                    "新赛道"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【中银医药】博雅生物事件点评：收购无锡罗益生物，跨入疫苗业务新赛道",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]